At a biohacking conference this week, a biotech CEO dropped his pants and injected himself in the thigh with an experimental herpes treatment created by his company, leaving other biohackers worried.
Scientists have tweaked the DNA in human heart cells to correct mutations that cause a deadly disease, which if proved safe could eventually cure children of Duchenne Muscular Dystrophy (DMD).
A new approach to treatment for certain melanoma patients may lead to better results after surgery, a new study suggests.
A new animal study involving virally-delivered gene therapies has indicated that high treatment doses might not be as safe as previous human trials have suggested
Drugmaker company, Roche has been granted FDA approval for its breakthrough therapy designation for Balovaptan to treat Autism Spectrum Disorder (ASD), potentially accelerating its development and approval.
Having a stock double in a year is pretty impressive, right? Writing for the Motley Fool, Keith Speights weighs in on three healthcare stocks that have done exactly that.
Although very much disagreeing with biohacking practices, and strongly discouraging them, the FDA has never actually intervened themselves with individuals. Should they?
A three-drug combination can simultaneously target pancreatic cancer cells, as well as the other harmful, inflammatory cells within tumours, according to new research.
Two new cancer treatments have shown miraculous cures, but if you happen to live in a handful of rural states in the U.S. (let alone outside the U.S.) — you’ll have to travel hundreds of miles to get them. And it’s by no means certain that they’ll eventually be available everywhere.
“My Greatest Achievement Has Been Overcoming My Own Shyness to Advocate My Disabled Child” – Judith Sheppard
Judith Sheppard is the parent of a 22-year-old young man with FOXG1 Syndrome. We’ve had a chat with her before her talk “Finding the Needle in the Haystack” at the Festival of Genomics in London 2018.